TD Cowen analyst Andrew Kligerman upgraded Arthur J. Gallagher (AJG) to Buy from Hold with a price target of $377, up from $295, following the ...

TD Cowen analyst Marc Frahm maintained a Buy rating on Repare Therapeutics (RPTX – Research Report) today. The company’s shares closed last ...

Fintel reports that on January 7, 2025, TD Cowen initiated coverage of KalVista Pharmaceuticals (NasdaqGM:KALV) with a Buy ...

Fintel reports that on January 8, 2025, TD Cowen upgraded their outlook for Coca-Cola (NYSE:KO) from Hold to Buy. Analyst ...

El Lilly’s blockbuster weight-loss drug Zepbound is now eligible for coverage under Medicare prescription drug plans, when ...

Lisa Thomas, Managing Director and Deputy Head of Global Research at TD Cowen, discusses some of the key findings of a new TD Cowen report on the big investment themes of 2025, including shifting ...

When the BIOSECURE Act hit a setback and missed the chance of becoming law in 2024, the deceleration of the draft legislation ...

The cost of prescription drugs is set to climb in 2025 and beyond, according to TD Cowen’s 30th Annual Drug Pricing survey.

“Two-thousand-twenty-four was a tough year for staples stocks, and 2025 is shaping up to be even tougher,” says TD Cowen ...

Rate hike expectations +30bps sequentially, though still below survey average. Biz growth & confidence stepped up ...

The S&P 500 gained 0.55% to close at 5,975.38. The Nasdaq Composite advanced 1.24% to end at 19,864.98. The Dow Jones ...

American Airlines' stock is poised for a strong 2025 as the carrier emerges from a challenging year, according to brokerages ...